• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Direct oral anticoagulants for the treatment of left ventricular thrombosis: an updated systematic review and meta-analysis
Conclusion Compared with VKAs, we found DOACs to have similar efficacy on thrombus resolution and favorable effects on stroke reduction and bleedings. DOACs should be considered as an alternative treatment for LVT. Large prospective randomized clinical trials are needed to confirm this exploratory finding.
Source: Journal of Cardiovascular Medicine - September 17, 2022 Category: Cardiology Tags: Research articles: Hear failure Source Type: research

ORal anticoagulants In fraGile patients with percutAneous endoscopic gastrostoMy and atrIal fibrillation: the (ORIGAMI) study
Conclusion ORIGAMI prospectively investigates PEG-administration of edoxaban in PEG-treated patients requiring long-term anticoagulation. Our preliminary retrospective data support this route of DOAC administration. ClinicalTrials.gov Identifier NCT04271293
Source: Journal of Cardiovascular Medicine - February 4, 2021 Category: Cardiology Tags: Research articles: Arrhythmias Source Type: research

Direct oral anticoagulants for patients aged over 80 years in nonvalvular atrial fibrillation: the impact of frailty
Conclusion Our study highlights how DOACs are a safe and effective option for anticoagulation, even in frail elderly people; the introduction of these drugs is leading to an increased use of anticoagulation therapy in this population. Prospective trials will be needed to reinforce these results and to consider new variables in the thrombotic and hemorrhagic risk scores underlying the prescription of DOACs.
Source: Journal of Cardiovascular Medicine - July 30, 2020 Category: Cardiology Tags: Research articles: Arrhythmias Source Type: research

Is oral anticoagulation effective in preventing transcatheter aortic valve implantation failure? A propensity matched analysis of the Italian Transcatheter balloon-Expandable valve Registry study
Conclusion After TAVI with Edwards Sapien valve OAT did not reduce the incidence of valve dysfunction and stroke but was responsible for mortality and bleeding increases.
Source: Journal of Cardiovascular Medicine - December 27, 2019 Category: Cardiology Tags: Research articles: Interventional cardiology Source Type: research

Insertable cardiac monitor detection of silent atrial fibrillation in candidates for percutaneous patent foramen ovale closure
Conclusion An occult preexisting atrial fibrillation may lead to unnecessary percutaneous foramen ovale closure in a significant proportion of patients. A 6-month loop-recorder monitoring may improve the patient oriented decision-making.
Source: Journal of Cardiovascular Medicine - April 2, 2019 Category: Cardiology Tags: Research articles: Arrhythmias Source Type: research

Persistence on apixaban in atrial fibrillation patients: a retrospective multicentre study
Conclusion In real-life conditions, NVAF patients treated with apixaban show rates of treatment discontinuation and major bleedings, which are comparable to those found in the ARISTOTLE pivotal study, thus supporting its external validity.
Source: Journal of Cardiovascular Medicine - January 3, 2019 Category: Cardiology Tags: Research articles: Arrhythmias Source Type: research

Design and rationale of the Edoxaban Treatment in routiNe clinical prActice for patients with Atrial Fibrillation in Europe (ETNA-AF-Europe) study
This study details the design of the Edoxaban Treatment in routiNe clinical prActice for patients with Atrial Fibrillation in Europe (ETNA-AF-Europe) study – a postauthorization observational study, which is part of the postapproval plan for edoxaban agreed with the European Medicines Agency. Methods The ETNA-AF-Europe study (Clinicaltrials.gov: NCT02944019) is a multicenter, prospective, observational study that enrolled 13 980 patients with atrial fibrillation treated with edoxaban from 852 sites across 10 European countries (Austria, Belgium, Germany, Ireland, Italy, the Netherlands, Portugal, Spain, Switzerland,...
Source: Journal of Cardiovascular Medicine - January 3, 2019 Category: Cardiology Tags: Research articles: Trial design Source Type: research

Percutaneous coronary intervention or coronary artery bypass graft in left main coronary artery disease: a comprehensive meta-analysis of adjusted observational studies and randomized controlled trials
Conclusion Surgical revascularization reduces risk of revascularization for ULMCA patients, especially for those with Syntax score greater than 22, with a higher risk of in-hospital death. Intra-coronary imaging and use of arterial grafts improved performance of revascularization strategies.
Source: Journal of Cardiovascular Medicine - August 31, 2018 Category: Cardiology Tags: Research articles: Interventional cardiology Source Type: research

Initial experience of percutaneous left atrial appendage closure using the LAmbre device for thromboembolic prevention
Conclusion The LAmbre occluder is a novel LAA-closure device with features that provide many options for LAA-closure to physicians, particularly in patients with challenging anatomies. From our initial experience, implantation is associated with a good success rate and clinical outcome.
Source: Journal of Cardiovascular Medicine - July 31, 2018 Category: Cardiology Tags: Research articles: Interventional cardiology Source Type: research

Is there a role for tissue Doppler imaging in predicting thromboembolic risk? A challenging case report of dilated cardiomyopathy with intracardiac thrombus and recurrent stroke
No abstract available
Source: Journal of Cardiovascular Medicine - July 31, 2018 Category: Cardiology Tags: Images in cardiovascular medicine Source Type: research

Thrombosis on a left atrial appendage occluder device: the double-edged sword of stroke prevention strategies in atrial fibrillation
A huge thrombus, developing after percutaneous left atrial appendage occlusion, has been successfully treated with dabigatran and aspirin as combination therapy. Although novel oral anticoagulants alone may be effective in thrombus dissolution, the association of an antiplatelet drug may safely enhance this process.
Source: Journal of Cardiovascular Medicine - October 7, 2017 Category: Cardiology Tags: Images in cardiology Source Type: research

Dabigatran in nonvalvular atrial fibrillation: from clinical trials to real-life experience
Atrial fibrillation is the most common arrhythmia in over-midlife patients. In addition to systolic heart failure, cerebral thromboembolism represents the most dramatic complication of this rhythm disorder, contributing to morbidity and mortality. Traditionally, anticoagulation has been considered the main strategy in preventing stroke and systemic embolism in atrial fibrillation patients and vitamin K-dependent antagonists have been widely used in clinical practice. Recently, the development of direct oral anticoagulants has certainly improved the management of this disease, providing, for the first time, the opportunity ...
Source: Journal of Cardiovascular Medicine - May 18, 2017 Category: Cardiology Tags: Reviews Source Type: research

Chagas disease as a cause of heart failure and ventricular arrhythmias in patients long removed from endemic areas: an emerging problem in Europe
We report two examples of Chagas cardiomyopathy in South American women permanently residing in Italy for more than 20 years, presenting with cardiac manifestations ranging from left ventricular dysfunction and heart failure to isolated ventricular arrhythmias. The present review emphasizes that Chagas disease should be considered as a potential diagnosis in patients from endemic areas presenting with ‘idiopathic’ cardiac manifestations, even when long removed from their country of origin, with potential implications for treatment and control of Chagas disease transmission.
Source: Journal of Cardiovascular Medicine - October 30, 2015 Category: Cardiology Tags: Arrhythmias Source Type: research

Novel oral anticoagulants in atrial fibrillation: which novel oral anticoagulant for which patient?
Atrial fibrillation is the most common rhythm disorder and represents a major public health problem because it carries an increased risk of arterial thromboembolism and ischemic stroke. Current european society of cardiology guidelines recommend to stratify atrial fibrillation patients according to the CHA2DS2-VASc score and to administer anticoagulation, preferably with novel oral anticoagulants, that is, dabigatran, rivaroxaban, or apixaban, if the CHA2DS2-VASc score is at least 1. All novel anticoagulants have shown the same, if not greater, efficacy and safety as warfarin, with some advantages. The choice among the nov...
Source: Journal of Cardiovascular Medicine - June 4, 2015 Category: Cardiology Tags: Anticoagulation: Review Source Type: research

Increased risk of myocardial infarction with dabigatran: fact or fiction?
Dabigatran is a direct, competitive inhibitor of thrombin recently approved for the prophylaxis of stroke and systemic embolism in patients with nonvalvular atrial fibrillation. In some of the clinical trials evaluating the efficacy and safety of dabigatran in different clinical settings [i.e., prevention of venous thromboembolism (VTE) after orthopedic surgery, secondary prevention of VTE, and acute coronary syndromes (ACS)], a trend toward an increase in acute coronary events among patients receiving dabigatran has been reported, thus raising concerns of a possible relationship between dabigatran and myocardial infarctio...
Source: Journal of Cardiovascular Medicine - January 1, 2014 Category: Cardiology Tags: Reviews: Antithrombotic treatment Source Type: research